<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-05-30T00:09:17Z</responseDate><request verb="GetRecord" identifier="oai:riuma.uma.es:10630/24735" metadataPrefix="marc">https://riuma.uma.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:riuma.uma.es:10630/24735</identifier><datestamp>2026-02-03T12:32:09Z</datestamp><setSpec>com_10630_2254</setSpec><setSpec>col_10630_37959</setSpec></header><metadata><record xmlns="http://www.loc.gov/MARC21/slim" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
   <leader>00925njm 22002777a 4500</leader>
   <datafield ind2=" " ind1=" " tag="042">
      <subfield code="a">dc</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Claros-Gil, Silvia</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Cabrera García, Pablo</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Valverde, Nadia</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Romero-Zerbo, Silvana Yanina</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Lara, Estrella</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">López-González, Manuel Víctor</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Shumilov, Kirill</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Rivera-Ramírez, Alicia</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Pavía-Molina, José</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">Martín-Montañez, Elisa</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="720">
      <subfield code="a">García-Fernández, María Inmaculada</subfield>
      <subfield code="e">author</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="260">
      <subfield code="c">2022-07-12</subfield>
   </datafield>
   <datafield ind2=" " ind1=" " tag="520">
      <subfield code="a">Aims: Parkinson’s disease (PD) affects 1–3% of the population aged over 65. Stress seems to contribute to&#xd;
PD neuropathology, probably by dysregulation of the hypothalamic–pituitary–adrenal axis. Key factors are&#xd;
oxidative stress, mitochondrial dysfunction and neuronal glucocorticoid-induced toxicity. Insulin-like growth&#xd;
factor II (IGF-II) has shown antioxidant and neuroprotective effects in some neurodegenerative disorders.&#xd;
Therefore, our aim was to study IGF-II protective effects against oxidative damage on a cellular combined&#xd;
model of PD and mild to moderate stress, based on corticosterone (CORT) and the dopaminergic&#xd;
neurotoxin 1-methyl-4-phenylpyridinium (MPP+).&#xd;
Methods: The dopaminergic neuronal cell line SN4741 (RRID:CVCL_S466) derived from mouse substantia&#xd;
nigra were exposed to 200 μM MPP+, 0.5 μM CORT or both, with or without 25 ng/mL IGF-II, for 2.5 or 6 h.&#xd;
Cell viability, oxidative stress parameters, mitochondrial and dopamine markers and intracellular signaling&#xd;
pathways were evaluated.&#xd;
Results: The administration of MPP+ or CORT individually led to cell damage compared to control&#xd;
situations, whereas the combination of both drugs produced very considerable toxic synergistic effect. IGF-II&#xd;
counteracts the mitochondrial-oxidative damage, protecting dopaminergic neurons from death and&#xd;
neurodegeneration. IGF-II promotes PKC activation and nuclear factor (erythroid-derived 2)-like 2&#xd;
antioxidant response in a glucocorticoid receptor-dependent pathway, preventing oxidative cell damage&#xd;
and maintaining mitochondrial function.&#xd;
Conclusions: IGF-II capacity to protect nigral dopamine neurons against mitochondrial-oxidative damage&#xd;
induced by CORT and MPP+ was demonstrated. Thus, IGF-II is a potential therapeutic tool for prevention&#xd;
and treatment of PD patients suffering mild to moderate emotional stress.</subfield>
   </datafield>
   <datafield ind1="8" ind2=" " tag="024">
      <subfield code="a">https://hdl.handle.net/10630/24735</subfield>
   </datafield>
   <datafield tag="653" ind2=" " ind1=" ">
      <subfield code="a">Insulina</subfield>
   </datafield>
   <datafield tag="653" ind2=" " ind1=" ">
      <subfield code="a">Parkinson, Enfermedad de</subfield>
   </datafield>
   <datafield ind2="0" ind1="0" tag="245">
      <subfield code="a">Insulin-like growth factor II neuroprotective effects against mitochondrial-oxidative and neuronal damage induced by CORT and MPP+ in dopaminergic neurons</subfield>
   </datafield>
</record>
</metadata></record></GetRecord></OAI-PMH>